Roberts PJ , Sharif NA. Effects of L‑glutamate and related amino acids upon the release of [3H]-dopamine from rat striatal slices. Brain Research, 157, 391‑394 (1978).
Sharif NA, Roberts PJ. Problems associated with binding of L‑glutamic acid to synaptic membranes ‑ methodological aspects. Journal of Neurochemistry, 34, 779‑784 (1980).
Roberts PJ, McBean GJ, Sharif NA , Thomas, EM. Striatal glutamatergic function: modification following specific lesions. Brain Research, 235, 83‑91 (1981).
Sharif NA , Roberts PJ. Regulation of cerebellar [3H]-glutamate binding: influence of guanine nucleotides and Na+ ions. Biochemical Pharmacology, 30, 3019‑3022 (1981).
Sharif NA, Burt DR, Towle AC, Mueller RA, Breese GR. Codepletion of serotonin and TRH induces apparent supersensitivity of spinal TRH receptors. European J. Pharmacology, 95, 301‑304 (1983).
Sharif NA, Burt DR. Receptors for thyrotropin‑releasing hormone (TRH) in the rabbit spinal cord. Brain Research, 270, 259‑263 (1983).
Sharif NA, Pilotte, NS & Burt, DR. Biochemical and autoradiographic studies of TRH receptors in sections of rabbit spinal cord. Biochemical Biophysical Research Communications, 116, 669‑674 (1983).
Sharif NA , Burt DR. Rat brain TRH receptors: kinetics, pharmacology, distribution and ionic effects. Regulatory Peptides., 7, 399‑411 (1983).
Pilotte NS, Sharif NA, Burt DR. Characterization and autoradiographic localization of TRH receptors in sections of rat brain. Brain Research, 293, 372‑376 (1984).
Sharif NA, Burt DR. Modulation of receptors for thyrotropin releasing hormone by benzodiazepines: brain regional differences. Journal of Neurochemistry, 43, 742‑746 (1984).
Sharif NA. Diverse roles of thyrotropin‑releasing hormone in brain, pituitary and spinal cord function. Trends Pharmacological Sciences (TIPs) 6, 119‑122 (1985).
Clark CR, Birchmore B, Sharif NA, Hunter JC, Hill RG, Horwell D, Hughes J. PD117302: a new kappa‑selective opioid agonist. British J. Pharmacology, 93, 618‑626 (1988).
Sharif NA. Chronic prolactin, gonadal and thyroid hormone treatments in vivo alter levels of TRH and muscarinic receptors in male and female rat tissues. Brain Research, 449, 364‑368 (1988).
Sharif NA. Chemical and surgical lesions of the rat olfactory bulb: changes in thyrotropin‑releasing hormone and other systems. Journal of Neurochemistry, 50, 388‑394 (1988).
Sharif NA, Hunter JC, Hill RG, Hughes, J. Bradykinin‑induced accumulation of [3H]inositol‑1‑phosphate in human embryonic pituitary tumor cells by activation of a B2‑receptor. Neuroscience Letters., 86, 279‑283 (1988).
Tones M, Sharif NA, Hawthorne JN. Phospholipid turnover during cell‑cycle traverse in synchronous Chinese‑Hamster ovary cells. Biochemical Journal, 249, 51‑56 (1988).
Sharif NA. Quantitative autoradiography of TRH receptors in discrete brain regions of different mammalian species. Annals New York Academy of Sciences , 553, 147‑175 (1989).
Eglen RM, Michel AD, Sharif NA, Swank S, Whiting RL. Pharmacological properties of the peptide, endothelin. British J. Pharmacology, 97, 1297‑1307 (1989).
Sharif NA, Towle AC, Burt DR, Mueller RA, Breese GR. Co-transmitters: differential effects of serotonin (5HT)‑depleting drugs on 5HT and TRH levels and their receptors in rat brain and spinal cord. Brain Research, 480, 365‑371 (1989).
Sharif NA, Durie E, Michel AD, Whiting RL. Dog cerebral cortex contains m‑, δ‑ and k‑opioid receptors at different densities: lack of evidence for sub‑types of k‑receptor using selective radioligands. Brain Research 510, 108‑114, (1990).
Ransom J, Cherwinski HM, Delmendo R, Sharif NA , Eglen R. Characterization of m4 muscarinic receptor Ca2+ responses in a subclone of PC‑12 cells by single cell flow cytometry. Journal Biological Chemistry, 266, 11738‑11745 (1991).
Sharif NA, To ZP, Whiting RL. Analogs of thyrotropin‑releasing hormone (TRH): receptor affinities in brains, spinal cords and pituitaries of different species. Neurochemical Research, 16, 95‑103 (1991).
Nunes JL, Sharif NA, Michel AD , Whiting RL. Dopamine D2‑receptors mediate hypothermia in mice: icv and ip effects of agonists and antagonists. Neurochemical Research 16, 1167‑1174 (1991).
Sharif NA, Wong EH, Loury D, Stefanich E, Eglen RM, Michel A, Whiting RL. Characteristics of 5HT3 binding sites in rat cerebral cortex, NG108‑15 and NCB‑20 neuroblastoma cells using [3H]-quipazine and [3H]-GR65630 binding. British J. Pharmacology, 102, 919‑925 (1991).
Ransom J, Cherwinski HM, Dunne JF, Sharif NA. Flow cytometric analysis of internal calcium mobilization via a B2‑bradykinin receptor in a subclone of PC12 cells. Journal of Neurochemistry, 56, 983‑989 (1991).
Sharif NA, Nunes JL, Whiting RL. Pharmacological characterization of NMDA‑receptor‑channel in rodent and dog brain and rat spinal cord using [3H]MK‑801 binding. Neurochemical Research, 16, 563‑569 (1991).
Ransom JT, Sharif NA, Dunne J, Momiyama M, Melching G. AT‑1 angiotensin receptors mobilize intracellular calcium in a subclone of NG108‑15 neuroblastoma cells. Journal of Neurochemistry 58, 1883‑1888 (1992).
Kubek MJ, Knoblach SM, Sharif NA, Burt DR, Butterbaugh GG, Fuson KS. TRH gene expression and receptors are differentially modified in limbic foci by seizures. Annals of Neurology 33, 70‑76 (1993).
Sharif NA, Xu S, Yanni JM. Histamine receptor‑subtype affinities, selectivities and potencies of emedastine (Emedine®), a novel H1‑selective antagonist, and other ocularly employed antihistamines. Drug Development Research 33, 448‑453 (1994).
Chidlow G, DeSantis LM, Sharif NA, Osborne NN. The characteristics of [3H]5‑hydroxytrytamine binding to iris‑ciliary body of the rabbit. Investigative Ophthalmology & Visual Science 36, 2238‑2245 (1995).
Blue D, Bonhaus D, Ford APD, Pfister J, Sharif NA, Shieh A, Vimont R, Williams T, Clarke DE. Functional evidence equating the pharmacologically‑defined α1A‑ and cloned α1C‑adrenoceptors: studies in the isolated perfused kidney of rat. British J. Pharmacology 115, 283‑294 (1995).
Sharif NA, Williams GW, DeSantis LM. Affinities of muscarinic drugs for [3H]N‑methylscopolamine (NMS) and [3H]-Oxotremorine (OXO) binding to a mixture of M1‑M4 muscarinic receptors: Use of NMS/OXO ratios to group compounds into potential agonist, partial agonist and antagonist classes. Neurochemical Research 20, 669‑674 (1995).
Sharif NA, Xu S, Yanni JM. Olopatadine (AL‑4943A; Patanol®): Ligand binding and functional studies on a novel, long acting H1‑selective histamine antagonist for use in allergic conjunctivitis. Journal Ocular Pharmacology & Therapeutics 12, 401-407 (1996).
Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular anti‑allergic and anti‑histaminic effects of Olopatadine (AL‑4943A; Patanol®), a novel drug for treating ocular allergic diseases. J. Pharmacology & Experimental Therapeutics 278, 1251-1260 (1996).
Wiernas TK, Griffin BW, Sharif NA. The expression of functionally-coupled bradykinin receptors in human corneal epithelial cells and their pharmacological characterization with agonists and antagonists. British J. Pharmacology 121, 649-656 (1997).
Sharif NA, Williams GW, Xu SX, Crider JY, Griffin BW, Davis TL. Pharmacological analysis of [3H]PGE1 / [3H]PGE2 and [3H]PGF2a binding in bovine corpus luteum: identification of EP3 and FP prostaglandin receptors and correlation with functional data. J. Pharmacology & Experimental Therapeutics 286, 1094-1102 (1998).
Sharif NA, Wiernas TK, Howe, WL, Griffin, BW, Offord, EA, Pfeifer, AMA. Human corneal epithelial cell functional responses to inflammatory agents and their antagonists. Investigative Ophthalmology & Visual Science 39, 2562-2571 (1998).
Sharif NA, Wiernas TK, Griffin BW, Davis TL. Pharmacology of [3H]-pyrilamine binding and the histamine-induced phosphoinositide turnover, Ca2+-mobilization and cytokine release from human corneal epithelial cells. British J. Pharmacology 125, 1336-1344 (1998).
Crider JY, Xu SX, Griffin BW, Sharif NA. Use of a semi-automated, robotic radioimmunoassay to measure cAMP generated by activation of DP-, EP2- and IP-prostaglandin receptors in human ocular and other cell-types. Prostaglandins, Leukotrienes & Essential Fatty Acids 59, 77-82 (1998).
Yanni JM, Weimer L,Sharif NA, Xu SX, Gamache D, Spellman J. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Archives Ophthalmology 117, 643-647 (1999).
Davis TL, Sharif NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J. Ocular Pharmacology & Therapeutics 15, 323-336 (1999).
Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta. Ophthalmologica Scandinavia 77, 33-37 (1999).
Sharif NA, Davis TL, Williams GW. [3H]AL-5848 (9-b-[+]fluprostenol): carboxylic acid of Travoprost (AL-6221), a novel FP-prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J. Pharmacy & Pharmacology 51, 685-594 (1999).
Sharif NA , Xu SX. Human retina contains polyamine-sensitive [3H]-ifenprodil binding sites: implications for neuroprotection? British J. Ophthalmology 83, 236-240 (1999).
Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel PGF2a analog with selective antagonist effects at the FP prostaglandin receptor. J. Pharmacology & Experimental Therapeutics 290: 1278-1284 (1999).
Sharif NA, Crider JY, Xu SX, Williams GW. Affinities, selectivities, potencies and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J. Pharmacology & Experimental Therapeutics 293: 321-328 (2000).
Davis TL, Sharif NA. Pharmacological characterization of [3H]-prostaglandin E2 binding to the cloned human EP4 prostanoid receptor. British J. Pharmacology 130: 1919-1926 (2000).
Ohia SE, Opere CA, Awe SO, Adams L,Sharif NA. Human, bovine and rabbit retinal glutamate-induced [3H]D-aspartate release: role in excitotoxicity. Neurochemical Research 25: 853-860 (2000).
Sharif NA, Crider JY, Davis TL. AL-3138 antagonizes FP prostanoid receptor-mediated inositol phosphates generation: comparison with some purported FP antagonists. J. Pharmacy & Pharmacology 52: 1529-1539 (2000).
Sharif NA, Williams GW, Davis TL. Pharmacology and autoradiography of human DP prostanoid receptors using [3H]-BWA868C, a DP receptor-selective antagonist radioligand. British J. Pharmacology 131: 1025-1038 (2000).
Thomas D, Papadopoulo O, Doshi R, Kapin MA, Sharif NA. Retinal ATP and phosphorus metabolites: reduction by hypoxia and recovery with MK-801 and diltiazem. Medical Science Research 28: 87-91 (2000).
Harris LC, Awe SO, Opere CA, LeDay AM, Ohia SE, Sharif NA. [3H]-Serotonin release from bovine iris-ciliary body: pharmacology of pre-junctional serotonin (5HT7) autoreceptors. Experimental Eye Research 73, 59-67 (2001).
Hellberg MR, Sallee V, McLaughlin M, Sharif NA, DeSantis L, Dean TR, Zinke PW. Preclinical efficacy of Travoprost (Travatan®), a potent and selective FP prostaglandin receptor agonist. J. Ocular Pharmacology & Therapeutics 17: 421-432 (2001).
Ohia SE, Awe SO, Opere CA, LeDay AM, Harris LC, Sharif NA. Hypoxia-induced [3H]-D-aspartate release from isolated bovine retina: modulation by calcium channel blockers and glutamatergic agonists and antagonists. Current Eye Research 23: 386-392 (2001).
Sharif NA, Crider JY, Xu SX, McLaughlin M, Davis TL. Levobetaxolol (Betaxonä): in vitro pharmacology, intraocular pressure lowering activity & autoradiographic localization of b–receptors in human eyes. Proc. Western Pharmacology Society 44: 65-68 (2001).
Rangisetty J, Dukat M, Dowd C, Herrick-Davis K, DuPre A, Gadepalli S, Teitler M, Kelly C, Sharif NA, Glennon R. 1-[2-methoxy-5-(3-phenylpropyl)]-2-aminopropane unexpectedly shows 5HT2A serotonin receptor affinity and antagonist character. J. Medicinal Chemistry 44: 3283-3291 (2001).
Harris LC, Awe SO, Opere CA, LeDay AM., Ohia SE, Sharif NA. Pharmacology of serotonin receptors modulating electrically-induced [3H]norepinephrine release from isolated mammalian iris-ciliary bodies. J. Ocular Pharmacology & Therapeutics 18: 339-348 (2002).
Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J. Ocular Pharmacology & Therapeutics 18: 313-324 (2002).
May JM, Chen H-H, Rusinko A, Lynch, VM, Sharif NA, McLaughlin MA. A novel and selective 5HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1—(2-aminopropyl) -8,9-dihydropyrano-[3,2-e]indole. J. Medicinal Chemsitry 46: 4188-4195 (2003).
Ohia SE, Awe SO, Opere CA, LeDay AM, Harris LC, Kulkarni K, Sharif NA. Glucose deprivation-induced [3H]-D-aspartate release from isolated bovine and human retinae. J. Ocular Pharmacol Ther. 19: 599-609 (2003).
Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmology & Visual Science 44: 715-721 (2003).
May JM, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5HT1A and 5HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J. Pharmacology & Expt. Therapeutics 306: 301-309 (2003).
Crider JY, Williams GW, Drace CD, Katoli P, Senchyna M, Sharif NA. Pharmacological characterization of a serotonin receptor (5HT7) stimulating cAMP production in human corneal epithelial cells. Invest. Ophthalmology & Visual Science 44: 4837-4844 (2003).
Selliah RD, Hellberg MR, Sharif NA, McLaughlin MA, Williams GW, Scott DA, Earnest D. Haggard KS, Dean DW, Delgado P, Gaines, MS, Conrow RE, Klimko PG. AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey. Biorganic Medicinal Chemistry Letters 14: 4525-4528 (2004).
Sharif NA, Drace CD, Williams GW, Crider JY. Cloned human 5HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation. J. Pharmacy & Pharmacology 56: 1267-1274 (2004).
Glennon RA, Bondarev ML, Khoran N, Young R, May JA, Hellberg MR, McLaughlin MA, Sharif NA. β-Oxygenated analogues of the 5HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J. Medicinal Chemistry 47: 6034-6041 (2004).
Sharif NA, Williams GW, Crider JY, Xu SX, Davis TL. Molecular pharmacology of the ocular hypotensive DP/EP2 class prostaglandin AL-6598 and localization of DP and EP2 receptor sites in human eyes. J. Ocular Pharmacology & Therapeutics 20: 489-508 (2004).
Patil RV, Sharif NA. Aquaporin channel-mediated water flow: drug discovery opportunities for ocular and otic diseases. Current Topics in Pharmacology 9: 97-106 (2005).
Sharif NA, Davis TL, Williams GW. Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections. J. Ocular Pharmacology & Therapeutics 21: 121-132 (2005).
Sharif NA, Kelly, CR, McLaughlin MA. Human trabecular meshwork cells express functional serotonin-2 (5HT2) receptors: role in IOP reduction. Invest. Ophthalmology & Visual Science. 47: 4001-4010 (2006).
Sharif NA, Senchyna M. Serotonin receptor subtype mRNA expression in human ocular tissues determined by RT-PCR. Molecular Vision 12: 1040-1047 (2006).
May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA. 1-((S)-2-Aminopropyl)-1H-indazol-6-ol: (AL-34662) A potent peripherally acting 5‑HT2 receptor agonist with ocular hypotensive activity. J. Medicinal Chemistry 49: 318-328 (2006).
Sharif NA, McLaughlin MA, Kelly CR. AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist. J. Ocular Pharmacology & Therapeutics 23: 1-13 (2007).
Sharif NA, Kaddour-Djebbar I, Abdel-Latif AA. Cat iris sphincter smooth muscle contraction: comparison of FP-class prostaglandin analog agonist activities. J. Ocular Pharmacology & Therapeutics 24: 152-163 (2008).
Dismuke WM, Sharif NA, Ellis DZ. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel. Invest. Ophthalmology & Visual Science 50: 3353-3359 (2009).
Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan G-L, Camras C. Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in cynomolgus monkey eyes. Experimental Eye Research 88: 386-397 (2009).
May JA, Sharif NA, Chen H-H, Liao JC, Kelly CR, Glennon RA, Young R, Li J-X, Rice KC, France CP. Pharmacological properties and discriminative stimulus effects of a novel and selective 5HT2 receptor agonist, AL-38022A [(S)-2- (8,9-dihydro-7H-pyrano [2,3g]indazol-1-yl)-1-methylethylamine]. Pharmacology, Biochemistry & Behavior 91 : 307-314 (2009).
Dibas A, Oku H, Fukuhara M, Kurimoto T, Ikeda T, Patil RV, Sharif NA, Yorio T. Changes in ocular aquaporins expression following optic nerve crush. Molecular Vision 16: 330-340 (2010).
Dismuke WM, Sharif NA,Ellis DZ. Endogenous regulation of human Schlemm’s canal cell volume by nitric oxide signaling. Invest. Ophthalmology & Visual Science 51: 5817-5824 (2010).
Katoli P, Sharif NA, Sule A, Dimitrijevich SD. NPR-B natriuretic peptide receptors in human corneal epithelium: mRNA, immunohistochemical, protein and biochemical pharmacology studies. Molecular Vision 16: 1241-1252 (2010).
Henderson AJ, Hadden M, Guo C, Douglas N, Decornez H, Hellberg MR, Rusinko A, McLaughlin M, Sharif NA, Drace C, Patil R. 2,3-Diaminopyrines as rho kinase inhibitors. Bioorganic Medicinal Chemistry Letters 20: 1137-1140 (2010).
Faulkner R, Sharif NA, Orr S, Craven R, Moster M, Sall K, Whitson J, Bethem R, Curtis M, Dahlin D. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN® or TRAVATAN®. J. Ocular Pharmacology & Therapeutics 26: 147-156 (2010).
Ramachandran C, Patil RV, Combrink K, Sharif NA, Srinivas SP. Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells. Molecular Vision 17: 1877-1890 (2011).
Sharif NA, Katoli P, Scott D, Li L, Kelly CR, Xu S, Husain S, Toris C, Crosson C. FR-190997, [AL-44205], a non-peptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys. Drug Development Research 75: 211-223 (2014).
Chen H-H, Namil A, Severns B, Ward J, Kelly CR, Drace C, McLaughlin MA, Yacoub S, Li B, Patil R, Sharif NA, Hellberg MR, Rusinko A, Pang I-H, Combrink KD. In Vivo optimization of 2,3-diaminopyrazine Rho kinase inhibitors. Bioorganic Medicinal Chemistry Letters 24: 1875-1879 (2014).
May JA, Sharif NA, McLaughlin MA, Chen H-H, Severns BS, Kelly CR, Holt WF, Young R, Glennon RA, Hellberg, MR, Dean TR. Ocular hypotensive response in non-human primates of (R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol [AL-37807] a selective 5-HT2 receptor agonist. J. Medicinal Chemistry 58 : 8818-8833 (2015).
Sharif NA. Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes. J. Ocular Pharmacology & Therapeutics 31: 131-145 (2015).
Patil R, Xu S, Rusinko A, Feng Z, Katoli P, May JA, Hellberg M, Sharif NA, Wax M, Irigoyen M, Clarke M, Bordeau B, McGraith S, Luche M, van Hoek A, Brittain T, Brown P, Colbert D, Kumari SS, Varadaraj K, Mitra AK, Carr G. Rapid identification of novel inhibitors of aquaporin-1 channel by high-throughput screening. Chemical Biology & Drug Design 87: 794-805 (2016).